tiprankstipranks
Trending News
More News >
Pennant Group Inc (PNTG)
NASDAQ:PNTG
Advertisement

Pennant Group (PNTG) AI Stock Analysis

Compare
90 Followers

Top Page

PNTG

Pennant Group

(NASDAQ:PNTG)

Rating:71Outperform
Price Target:
$27.00
▲(11.16% Upside)
The overall stock score is primarily driven by strong financial performance and positive earnings call outcomes, indicating growth potential. However, high leverage and valuation concerns, along with regulatory challenges, temper the outlook.
Positive Factors
Acquisition Progress
Signature integration appears to be going well, and PNTG has seen strong retention of clinical staff.
Financial Performance
Strong Q1 across segments, with Home Health & Hospice outperformance more notable.
M&A Integration
Increasing estimates based on Q1 performance, high-end of guidance commentary and positive update on Signature integration process.
Negative Factors
Cash Flow Concerns
Operating cash flow did not meet expectations, highlighting potential challenges in financial management post-acquisition.
Operating Cash Flow
Q1 operating cash flow was below estimates, however company cited weakness was a function of acquisitions and timing rather than poor cash collection.

Pennant Group (PNTG) vs. SPDR S&P 500 ETF (SPY)

Pennant Group Business Overview & Revenue Model

Company DescriptionThe Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.
How the Company Makes MoneyPennant Group generates revenue through multiple streams within the healthcare services industry. Primarily, it earns money by providing home health services, hospice care, and long-term care services to patients, which are reimbursed through government programs such as Medicare and Medicaid, as well as private insurance providers. The company also benefits from strategic partnerships and affiliations with local healthcare providers and hospitals, which help to drive patient referrals and enhance service offerings. Additionally, Pennant Group may engage in value-based care models that incentivize improved patient outcomes, further contributing to its revenue through performance-based reimbursements.

Pennant Group Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Mar 04, 2026
Earnings Call Sentiment Positive
The earnings call reflected strong financial performance and growth across key segments, including significant revenue and EBITDA increases. However, regulatory challenges in the home health sector and ongoing hospice cap issues in California present notable concerns. The overall sentiment is cautiously optimistic, with raised guidance indicating confidence in overcoming these challenges.
Q2-2025 Updates
Positive Updates
Strong Revenue and EBITDA Growth
Q2 2025 revenue increased by $50.8 million or 30.1% to $219.5 million, and adjusted EBITDA increased by $3.2 million or 24.5% over the prior year quarter.
Home Health and Hospice Segment Performance
Segment revenue was $166 million, a 32.5% increase, and adjusted EBITDA was $25.5 million, a 29.9% increase. Hospice revenue was $73.8 million, a 24.3% increase, and admits increased by 14.7%.
Senior Living Segment Improvement
Revenue improved to $53.5 million, a 23.1% increase, with adjusted EBITDA improving by 25.7% over the prior year.
Acquisitions and Expansion
Announced purchase of divested assets from Amedisys and UnitedHealth Group, expanding presence in the Southeast U.S. and increasing capacity for future growth.
Raised Annual Guidance
Full-year revenue guidance increased to $852.8 million to $887.6 million, with adjusted EPS expected between $1.09 and $1.15, a 19.1% increase over 2024.
Negative Updates
Home Health Regulatory Challenges
CMS' proposed 2026 home health rule threatens a 6.4% reduction in payments, impacting traditional Medicare revenue and potentially affecting managed care contracts.
Hospice Cap Expense
Ongoing hospice cap expense issues in California are impacting results, despite progress in resolving exposures.
Company Guidance
During the Pennant Group's second quarter 2025 earnings call, the company reported substantial growth across its service lines, leading to an upward revision of its annual guidance. In Q2, Pennant generated revenue of $219.5 million, marking a 30.1% increase from the prior year, and adjusted EBITDA of $16.4 million, up by 24.5%. The company also raised its full-year revenue guidance to between $852.8 million and $887.6 million, with adjusted earnings per share projected between $1.09 and $1.15. This reflects a midpoint increase of $0.05 over the original 2025 guidance and a 19.1% growth over 2024's adjusted EPS. Key performance metrics highlighted include a 32.5% increase in Home Health and Hospice segment revenue, with hospice revenue up by 24.3%, and a 23.1% rise in Senior Living segment revenue. The call also addressed the company's strategic acquisition of assets from UnitedHealth Group and Amedisys, expected to add significant value and expansion into the Southeast U.S. market.

Pennant Group Financial Statement Overview

Summary
Pennant Group demonstrates strong revenue growth and improved cash flow generation, contributing to a positive financial outlook. However, the company faces challenges with relatively low profit margins and high leverage, which could pose risks if not managed carefully.
Income Statement
75
Positive
The income statement shows a solid revenue growth rate of 6.78% TTM, indicating a positive trend in sales. Gross profit margin is stable around 13.5%, and net profit margin has improved to 3.36% TTM. EBIT and EBITDA margins are also showing slight improvements, reflecting better operational efficiency. However, the margins are still relatively low, suggesting room for improvement in profitability.
Balance Sheet
65
Positive
The balance sheet reveals a high debt-to-equity ratio of 1.00 TTM, indicating significant leverage, though it has improved from previous years. Return on equity is at 9.94% TTM, showing decent profitability relative to equity. The equity ratio is moderate, suggesting a balanced asset structure. While leverage is a concern, the company is managing to improve its equity position.
Cash Flow
80
Positive
Cash flow analysis shows a remarkable free cash flow growth rate of 271.98% TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.40 TTM, and the free cash flow to net income ratio is 0.78 TTM, both reflecting healthy cash conversion. The company has significantly improved its cash flow position, enhancing financial flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue798.92M695.24M544.89M473.24M439.69M390.95M
Gross Profit108.17M93.76M67.04M58.59M45.74M54.89M
EBITDA51.95M44.44M30.64M24.60M9.46M23.82M
Net Income26.82M22.56M13.38M6.64M2.15M15.74M
Balance Sheet
Total Assets751.42M679.52M539.69M512.12M530.30M506.98M
Cash, Cash Equivalents and Short-Term Investments14.38M24.25M6.06M2.08M5.19M43.00K
Total Debt313.45M273.09M329.63M326.57M355.24M319.00M
Total Liabilities417.79M367.56M394.18M386.46M416.05M405.80M
Stockholders Equity313.30M293.28M140.34M121.01M110.20M96.58M
Cash Flow
Free Cash Flow32.42M30.31M24.98M-5.13M-24.53M42.95M
Operating Cash Flow41.68M39.30M33.09M9.04M-18.22M50.20M
Investing Cash Flow-97.76M-70.68M-30.22M-24.24M-20.12M-41.62M
Financing Cash Flow67.42M49.57M1.11M12.08M43.49M-8.95M

Pennant Group Technical Analysis

Technical Analysis Sentiment
Negative
Last Price24.29
Price Trends
50DMA
24.81
Negative
100DMA
26.24
Negative
200DMA
26.53
Negative
Market Momentum
MACD
-0.11
Positive
RSI
45.87
Neutral
STOCH
30.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PNTG, the sentiment is Negative. The current price of 24.29 is below the 20-day moving average (MA) of 24.94, below the 50-day MA of 24.81, and below the 200-day MA of 26.53, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 45.87 is Neutral, neither overbought nor oversold. The STOCH value of 30.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PNTG.

Pennant Group Risk Analysis

Pennant Group disclosed 42 risk factors in its most recent earnings report. Pennant Group reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pennant Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$832.25M31.0611.44%30.58%24.86%
71
Outperform
$1.30B37.547.02%2.09%16.24%116.58%
68
Neutral
$1.14B111.872.28%5.17%-65.33%
59
Neutral
$1.69B109.3142.49%11.53%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
51
Neutral
$486.20M-53.33%31.37%34.94%
46
Neutral
$1.82B-108.91%3.99%-14.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PNTG
Pennant Group
24.29
-8.08
-24.96%
BKD
Brookdale Senior Living
7.69
0.78
11.29%
SNDA
Sonida Senior Living
25.80
-0.22
-0.85%
HCSG
Healthcare Services
15.83
5.32
50.62%
USPH
US Physical Therapy
85.64
3.72
4.54%
AVAH
Aveanna Healthcare Holdings
8.22
2.74
50.00%

Pennant Group Corporate Events

Business Operations and StrategyFinancial Disclosures
Pennant Group Reports Strong Q2 2025 Financial Results
Positive
Aug 6, 2025

The Pennant Group reported its second quarter 2025 financial results, highlighting a significant increase in revenue and earnings compared to the previous year. Total revenue for the quarter was $219.5 million, marking a 30.1% increase, while net income rose by 24.5% to $7.1 million. The company also provided updated guidance for 2025, anticipating total revenue between $852.8 million and $887.6 million, reflecting strong operational momentum and potential growth opportunities, including a transaction with UnitedHealth Group and Amedisys.

Executive/Board ChangesShareholder Meetings
Pennant Group Holds Annual Stockholders Meeting
Neutral
May 20, 2025

On May 16, 2025, The Pennant Group, Inc. held its Annual Meeting of Stockholders, with 28,085,566 shares present either in person or by proxy. During the meeting, significant decisions were made, including the election of Stephen M.R. Covey and Suzanne D. Snapper as Class III directors, approval of an amendment to the certificate of incorporation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2025. Additionally, the Amended and Restated 2019 Omnibus Incentive Plan was approved, and the compensation for the company’s executive officers received advisory approval.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025